Patients with KRAS wild‐type disease and early‐onset pancreatic cancer (EOPC) harbored actionable mutations including BRAF, EGFR, ERBB2, and MAP2K1/2.PGVs in PALB2, BRCA2, and ATM were associated with high PDAC risk in the Chinese population. Here, EGFR is linked to pancreatic neoplasm.